Transactions on Materials, Biotechnology and Life Sciences
ISSN: 2960-1932, eISSN: 2960-2319 | Volume 7
MISBP 2024

Genetic Insights and Predictive Models in Alzheimer's Disease

Shuting Zhu *

Shanghai Starriver Bilingual School, Shanghai, China

* Corresponding Author: zhu_shuting@outlook.com

Abstract. Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by a significant genetic component, making the identification of genetic risk factors critical for predicting disease onset and progression. This review explores the genetic characteristics associated with AD, focusing on key genes such as APOE, APP, PSEN1, and PSEN2, and their roles in amyloid deposition, tau tangles, and overall disease pathology. By utilizing genetic databases like the Alzheimer's Disease Neuroimaging Initiative (ADNI), AlzGene, and the National Alzheimer's Coordinating Center (NACC), researchers can integrate genetic findings with neuroimaging techniques such as magnetic resonance imaging (MRI) and positron emission tomography (PET) to better understand the interplay between genetic, environmental, and lifestyle factors in AD development. In addition, advanced machine learning models, including support vector machines (SVM), random forest (RF), convolutional neural networks (CNN), autoencoders (AE), and deep learning algorithms, combined with Polygenic Risk Scores (PRS), are increasingly used to integrate genetic, imaging, and clinical data for more precise AD risk prediction. While these advancements offer promising pathways for early diagnosis and intervention, significant challenges remain. These include difficulties in data integration across diverse sources, the development of robust and personalized predictive models, and addressing ethical concerns related to the use of genetic data. Future research will need to focus on overcoming these challenges to create more effective personalized prediction models that incorporate genetic, environmental, and lifestyle factors. Such developments hold the potential to revolutionize early detection, diagnosis, and treatment strategies for AD.

Keywords: Alzheimer's Disease; Genetic Risk Factors; Polygenic Risk Score; Machine Learning Models.

1. Introduction

Alzheimer's Disease (AD) is a progressive neurodegenerative disorder, predominantly affecting the elderly, and is characterized by a gradual decline in cognitive functions. Clinically, AD presents with symptoms of dementia, impacting various cognitive domains such as orientation, comprehension, memory, thinking, calculation, learning ability, language, and judgment [1]. What distinguishes AD from other forms of dementia and normal aging is its subtle onset of cognitive decline in the presence of clear consciousness, with short-term memory loss often being an early and hallmark symptom.

On a biological level, AD is primarily marked by the accumulation of extracellular amyloid plaques and intraneuronal neurofibrillary tangles (NFTs) within the brain. These pathological features are closely associated with the degeneration of neurons, ultimately leading to brain atrophy. Amyloid plaques consist of β-amyloid peptides (Aβ), while NFTs are formed by hyperphosphorylated tau proteins, both of which contribute significantly to neuronal dysfunction and death.

Epidemiologically, AD is a major public health concern. The World Alzheimer's Report indicated that in 2015, over 45 million individuals worldwide were living with AD, a figure projected to double every 20 years [2]. It is currently the fifth leading cause of death globally, adding to the urgency of developing effective diagnostic and therapeutic strategies [2]. Given the increasing prevalence of AD and the profound burden it imposes on patients, families, and healthcare systems, early diagnosis and intervention are essential.

Content from this work may be used under the terms of CC BY-NC 4.0 licence (https://creativecommons.org/licenses/by-nc/4.0/).
Published by Warwick Evans Publishing.

The investigation of genetic factors becomes to an important way to identifying individuals at risk for AD. Many patients present with specific genetic mutations, such as those in the apolipoprotein E (APOE) gene, particularly the ε4 allele, which is strongly associated with sporadic AD cases and accounts for up to 60–80% of heritability [3]. Among familial AD cases, particularly those with early-onset (before the age of 65), mutations in the presenilin 1 (PSEN1), presenilin 2 (PSEN2), and amyloid precursor protein (APP) genes are responsible for approximately 70% of cases [4]. These genetic alterations contribute to neuronal dysfunction, triggering the cognitive decline seen in AD. Therefore, understanding these genetic markers offers a promising pathway for predicting AD risk, especially in elderly populations.

Identifying the genetic underpinnings of AD and developing predictive models based on these findings are crucial for advancing early diagnosis and intervention strategies. By targeting genetic factors, potential therapeutic approaches can be devised to slow the progression of the disease, offering patients a better quality of life. Recent advancements in neuroinformatics and bioinformatics have greatly facilitated this effort. These fields enable researchers to integrate genetic data with advanced computational and imaging techniques, allowing for the analysis of large datasets and the establishment of predictive models that link genetic risk factors to AD progression. Consequently, these models hold the potential to enhance early detection and inform more personalized treatment strategies.

The aim of this review is to provide a comprehensive overview of the genetic characteristics associated with Alzheimer's Disease and their application in predicting the risk of developing the condition. The review will focus on key genes, including APOE, APP, PSEN1, and PSEN2, and will explore the role of genetic databases, imaging technologies, and predictive models in advancing our understanding of AD. By synthesizing current research, this review seeks to highlight the significance of genetic factors in AD and their potential applications in clinical practice.

2. Genetic Characteristics of Alzheimer's Disease

2.1. Key Genes and Their Functions

2.1.1. APOE4 Gene.

The APOE4 gene is one of the most significant genetic risk factors for late-onset Alzheimer's disease (LOAD) [5]. The apolipoprotein E (APOE) gene, located on chromosome 19, has three major alleles: APOE2, APOE3, and APOE4 [5]. While the APOE2 allele has been shown to decrease the risk of Alzheimer's disease (AD) and promote longevity, its precise protective mechanism remains unclear. The APOE3 allele, being the most common, has no significant impact on the risk of AD [6]. In contrast, the APOE4 allele is associated with an increased risk of AD, as it not only has more toxic effects but also limits the protective functions of glial cells. Individuals carrying one copy of the APOE4 allele have a 3-4 times higher risk of developing AD, while those with two copies face an 8-12 times increased risk [6].

The APOE4 allele affects AD risk primarily through its impact on lipid metabolism and amyloid-β (Aβ) clearance in the brain. The brains of APOE4 carriers are less efficient at clearing amyloid plaques, leading to their accumulation, which in turn causes neuronal damage characteristic of AD pathology. However, the presence of APOE4 alone is not sufficient to cause AD. Environmental factors and interactions with other genetic elements also play a substantial role. Recent epidemiological studies suggest that lifestyle and environmental factors may interact with APOE alleles to modulate the risk of developing AD [7]. Factors such as physical exercise, diet, education, traumatic brain injury, smoking, and even sunlight exposure are under investigation for their interactions with APOE alleles [7]. Interestingly, younger preclinical APOE4 carriers may benefit most from preventive lifestyle interventions, while older non-carriers with dementia may experience the most pronounced effects.

2.1.2. APP, PSEN1, PSEN2 Genes.

The APP, PSEN1, and PSEN2 genes are closely associated with early-onset familial Alzheimer's disease (EOFAD). The APP (amyloid precursor protein) gene, located on chromosome 21, encodes a protein responsible for generating amyloid-β (Aβ) [7]. Mutations in APP lead to an overproduction of amyloid-β peptides, the building blocks of amyloid plaques. The PSEN1 (presenilin 1) and PSEN2 (presenilin 2) genes, located on chromosomes 14 and 1, respectively, encode critical components of the γ-secretase complex, responsible for the cleavage of APP. Mutations in these genes result in the increased production of the toxic amyloid-β42 peptide, which aggregates to form plaques, contributing to the pathology of AD.

These genes are primarily associated with EOFAD and are useful in identifying individuals at high risk for early-onset AD. Mutations in PSEN1, PSEN2, and APP are major pathogenic causes of early-onset AD, accounting for about 5% of AD cases [8]. Genetic testing for these mutations is recommended for families with a history of early-onset AD, providing opportunities for early diagnosis and potential intervention.

2.2. Other Relevant Genes

Recent advancements in genome-wide association studies (GWAS) have identified several additional genes associated with an increased risk of AD, including CLU (clusterin), PICALM (phosphatidylinositol-binding clathrin assembly protein), and CR1 (complement component 3b/4b receptor 1) [9]. These genes contribute to the complex genetic landscape of AD.

CLU is involved in lipid transport and amyloid clearance. Variants in the CLU gene have been linked to altered amyloid-β metabolism and increased AD risk. PICALM plays a role in clathrin-mediated endocytosis and synaptic function. Variants in PICALM have been shown to affect neuronal communication and amyloid-β clearance, influencing susceptibility to AD. CR1, part of the immune system's complement pathway, is associated with a reduced ability to clear amyloid-β from the brain, thereby increasing AD risk.

These genes provide valuable targets for potential therapeutic interventions and help to further understand AD risks across diverse populations. Genetic polymorphisms in these genes may also explain variations in disease onset and progression among different ethnic and genetic groups.

3. Databases and Their Application in Genetic Research

3.1. Common Alzheimer's Disease Gene Databases

3.1.1. ADNI Database.

The Alzheimer's Disease Neuroimaging Initiative (ADNI) is one of the most comprehensive databases for studying Alzheimer's disease. ADNI collects and shares clinical, imaging, genetic, and biochemical data from individuals across various stages of cognitive decline, ranging from normal aging to AD. ADNI leverages imaging, blood, cerebrospinal fluid (CSF) analysis, and postmortem neuropathological data to identify markers associated with AD [10]. The ADNI project is a global collaboration involving countries such as the United States, China, Japan, and others [10].

ADNI's genetic data include results from genome-wide association studies (GWAS) and whole-genome sequencing (WGS), which are invaluable for identifying AD-related genetic variants. Researchers can combine genetic data with neuroimaging results, such as structural MRI and PET scans, to investigate the relationships between specific genes and brain changes associated with AD. ADNI has been instrumental in identifying new biomarkers for early diagnosis and tracking disease progression.

3.1.2. AlzGene Database.

AlzGene is a resource that compiles genetic association studies related to Alzheimer's disease. It aggregates data from multiple studies, facilitating meta-analyses that consistently identify genetic risk factors across diverse populations. AlzGene provides a ranked list of genetic variants most strongly associated with AD [11]. It is a key tool for large-scale genetic research and for verifying previously identified genetic links. The database also helps researchers explore gene-gene interactions and their combined effects on AD risk.

3.1.3. NACC Database.

The National Alzheimer's Coordinating Center (NACC) is another valuable resource for Alzheimer's disease research. Established in 1999, NACC maintains a comprehensive database that collects longitudinal data from Alzheimer's Disease Research Centers (ADRCs) across the United States [12]. The NACC database includes extensive clinical, genetic, and neuropathological data from thousands of individuals, including those with Alzheimer's disease, mild cognitive impairment (MCI), and normal cognition.

NACC is particularly significant because of its inclusion of diverse populations, allowing researchers to study genetic variations across different ethnic and demographic groups. The database also includes autopsy-confirmed diagnoses, providing a high level of accuracy in identifying AD-related genetic factors. Researchers can access a wide range of data types, including genetic information, neuroimaging results, cognitive assessments, and clinical histories. This extensive dataset enables robust analyses of genetic risk factors and their correlations with clinical and neuropathological outcomes, making NACC a critical tool for advancing personalized medicine and improving the precision of Alzheimer's disease risk prediction models. The researchers can get accessible collection and management of the data by using the system.

3.2. Data Integration and Analysis

Integrating data from multiple databases is crucial for large-scale genetic analyses, such as GWAS and whole-exome sequencing (WES). These methods allow researchers to scan the genome for novel genetic variants linked to AD. To handle these large datasets, advanced bioinformatics tools like PLINK and polygenic risk score (PRS) calculators are used [13].

In AD research, studying gene-environment interactions is key. Environmental factors such as diet, exercise, and exposure can interact with genetic risk factors, influencing disease development. Data management strategies must account for these interactions to provide a more complete understanding of AD risk. Furthermore, privacy and ethical considerations in handling sensitive genetic data are of utmost importance, ensuring compliance with regulations regarding privacy, consent, and data sharing.

These databases and tools provide a foundation for ongoing research into the genetic basis of Alzheimer's disease, enabling the discovery of novel biomarkers and the development of predictive models.

4. Application of Imaging Technologies in Gene and Disease Prediction

4.1. Magnetic Resonance Imaging (MRI)

4.1.1. Structural MRI.

Structural MRI is a pivotal tool in Alzheimer's disease (AD) research, providing high-resolution images of brain anatomy, which are essential for detecting the characteristic structural changes associated with AD. The medial temporal lobe, particularly the entorhinal cortex and hippocampus, is one of the earliest regions to show atrophy in AD patients [14]. This reduction in hippocampal volume is often used as a biomarker for early diagnosis, as it reflects the loss of neurons critical to

memory function [15]. Structural MRI can also detect volume reductions in other regions, such as the entorhinal cortex and amygdala, and cortical thinning in areas including the temporal, orbitofrontal, and parietal regions. The identification of these patterns, often referred to as the "disease signature," plays a critical role in distinguishing AD from normal aging and other forms of dementia [15].

When combined with genetic data, structural MRI offers insight into how specific genetic variants influence brain morphology. For example, individuals carrying the APOE4 allele, a well-established genetic risk factor for AD, exhibit more pronounced hippocampal atrophy and cortical thinning than non-carriers, even before the onset of clinical symptoms [16]. This integration of genetic and imaging data improves the early detection of AD and helps identify high-risk individuals, potentially allowing for early interventions that could slow disease progression.

4.1.2. Functional MRI (fMRI).

Functional MRI (fMRI) is another valuable imaging technique, capable of measuring brain activity by detecting blood-oxygen-level-dependent (BOLD) signals, which reflect neuronal activity. In AD research, fMRI is used to explore disruptions in functional connectivity, particularly in brain networks related to memory and cognition, such as the default mode network (DMN) [17]. Alterations in these networks, often observed in AD patients, are linked to the cognitive impairment characteristic of the disease.

Integrating fMRI data with genetic analyses allows researchers to investigate how genetic risk factors influence brain function. For instance, APOE4 carriers have been found to exhibit abnormal functional connectivity in memory-related regions, even in the absence of cognitive symptoms [16]. These findings highlight the potential of fMRI as a tool for identifying preclinical changes in brain activity, which could lead to the development of targeted interventions tailored to an individual's genetic profile.

4.2. Positron Emission Tomography (PET)

4.2.1. PET in Alzheimer's Disease.

Positron Emission Tomography (PET) is a powerful imaging technology that provides insights into the molecular processes underlying AD. PET is particularly useful for detecting the accumulation of amyloid-β plaques and tau tangles, the two pathological hallmarks of AD [15]. In addition to amyloid and tau imaging, fluorodeoxyglucose PET (FDG-PET) can measure cerebral glucose metabolism, offering an indicator of neuronal activity in AD patients.

By combining PET imaging with genetic data, researchers can better understand how genetic variants contribute to the development of AD. For instance, APOE4 carriers tend to exhibit higher amyloid plaque burden at an earlier age than non-carriers, making PET a valuable tool for identifying preclinical stages of the disease [16]. PET imaging also facilitates the longitudinal tracking of amyloid and tau deposits, enabling researchers to monitor disease progression and evaluate the effectiveness of therapeutic interventions aimed at reducing these pathological markers.

4.2.2. Multimodal Imaging Approaches.

Multimodal imaging, which integrates data from various imaging techniques such as PET, MRI, and EEG, offers a comprehensive view of the structural, functional, and molecular changes associated with AD [18]. By combining PET imaging of amyloid or tau with structural MRI data, researchers can correlate the molecular burden of AD with brain atrophy, providing a more complete understanding of disease progression.

When combined with genetic information, multimodal imaging enhances the ability to predict disease onset and progression. For example, individuals carrying the APOE4 allele who exhibit both amyloid accumulation on PET and hippocampal atrophy on MRI are at a higher risk for rapid cognitive decline [16]. This integrated approach not only aids in early detection but also supports the development of

personalized treatment strategies, as it identifies specific biomarkers that are most predictive of AD in different genetic subgroups.

5. Application of Genetic Features in Alzheimer's Disease Risk Prediction

5.1. Polygenic Risk Score (PRS)

The Polygenic Risk Score (PRS) is a powerful tool for estimating an individual's genetic predisposition to Alzheimer's disease by analyzing the combined effects of multiple genetic variants across the genome [19]. Genome-wide association studies (GWAS) have identified approximately 40 single nucleotide polymorphisms (SNPs) significantly associated with AD [20]. These findings suggest that AD is not caused by a single gene, but by the cumulative effect of many genetic risk factors.

PRS has shown great potential in AD prediction, with recent studies demonstrating an accuracy of up to 84% in identifying individuals at risk for the disease [20]. The score incorporates both common and rare genetic variants, providing a comprehensive risk estimate. For example, a high PRS that includes genes such as APOE, APP, and CLU indicates an elevated likelihood of developing AD. Advances in computational biology have further improved the accuracy of PRS by allowing the integration of large-scale genetic datasets.

To enhance prediction accuracy, some studies recommend applying a p-value threshold (pT) < 0.1 when selecting SNPs for inclusion in the PRS, particularly when focusing on the APOE gene [19]. This refinement helps maximize the score’s predictive value, making it a useful tool for early identification of individuals who may benefit from preventive interventions before cognitive decline becomes apparent.APP, PSEN1, PSEN2 Genes.

5.2. Machine Learning and Predictive Models

Machine learning has revolutionized Alzheimer's disease research by enabling the development of sophisticated predictive models that analyze complex, multidimensional data. Algorithms such as support vector machines (SVM), random forest (RF), convolutional neural networks (CNN), and autoencoders (AE) have been applied to genetic, imaging, and clinical data to predict AD risk with increasing precision [21].

SVM algorithms classify individuals into risk categories based on genetic and imaging data. Khedher et al. achieved an accuracy of 88.49%, specificity of 91.27%, and sensitivity of 85.11% using SVM as classifiers [22]. RF algorithms, which build decision trees based on input variables such as genetic variants and imaging biomarkers, are also effective in predicting AD risk [23]. CNNs, particularly adept at processing spatial data like brain images, are widely used in AD research to detect subtle structural changes associated with the disease [21]. Autoencoders, which reduce the dimensionality of high-dimensional data like genomic or neuroimaging data, enhance feature extraction and improve predictive accuracy [21].

Deep learning models, a subset of machine learning, have shown particular promise in AD prediction, as they can learn patterns from large datasets and improve accuracy over time. Transformers, which handle sequential data, are well-suited for modeling longitudinal changes in cognitive decline or brain structure [21]. These models, especially when integrated with genetic data, offer the potential for earlier and more accurate AD diagnosis.

5.3. Clinical Application of Predictive Models

Predictive models based on genetic risk have the potential to revolutionize clinical practice by enabling early diagnosis and personalized treatment. Identifying individuals at high genetic risk for AD allows for timely interventions, such as lifestyle modifications, cognitive training, or pharmacological treatments, aimed at delaying or preventing disease onset.

One promising application is the use of genetic risk models to guide early intervention strategies for high-risk individuals, such as APOE4 carriers, who may benefit from preventive therapies even before cognitive symptoms manifest. These models also hold the potential to tailor treatment plans to an individual's genetic profile, enhancing the efficacy of therapeutic interventions. Furthermore, by incorporating genetic diversity, predictive models can be adapted to different populations, improving their broad applicability.

However, the use of predictive models in clinical settings must be carefully managed, considering the variability in prediction accuracy across different populations and datasets. Ethical concerns, including the psychological impact of disclosing genetic risk and the potential for genetic discrimination, must also be addressed. Despite these challenges, ongoing refinements in predictive modeling are likely to make them a valuable tool in the early diagnosis and prevention of AD.

6. Challenges and Future Directions

6.1. Data Integration and Analytical Challenges

A significant challenge in Alzheimer's disease (AD) prediction models is the integration of diverse data sources, including genetic, imaging, and clinical data. Each data type presents unique complexities—genetic data is vast and often difficult to interpret, imaging data can vary in quality and consistency, and clinical data may be incomplete or noisy, especially in the early stages of cognitive decline [24]. Merging these different data types into a cohesive predictive framework requires sophisticated computational techniques and substantial computational power.

Moreover, the lack of standardized data formats across studies and databases hinders efforts to build comprehensive models. Shallow models, such as traditional random forests, struggle to manage the noise and missing data in clinical datasets, often leading to inaccurate predictions [25]. While deep learning models have shown promise in handling noisy data from single modalities, the small sample sizes typically available for such models in AD research limit their applicability [25]. The development of data harmonization tools and improved interoperability remains ongoing, and overcoming these challenges is essential for creating generalized models that can be used across diverse populations.

Another significant issue in model development is overfitting, where models perform well on training data but fail to generalize to new, unseen data. Addressing this issue requires improved algorithms and validation techniques to ensure that models can be applied effectively in real-world settings.

6.2. Personalized Prediction and Therapy

The future of Alzheimer’s disease management lies in personalized prediction and therapy—tailoring prevention, diagnosis, and treatment based on an individual’s genetic profile, lifestyle, and environmental exposures. Predictive models that incorporate these factors offer the potential to assess the likelihood of individuals with cognitive decline progressing to AD [26]. Integrating multi-omics data—genomics, proteomics, and metabolomics—into these models could further enhance prediction accuracy and help identify specific pathways involved in disease progression.

Artificial intelligence (AI) is also playing an increasingly critical role in advancing AD prediction models. AI has the capacity to process large datasets and track patient dynamics, allowing for early diagnosis, continuous monitoring, and intervention [27]. Despite these advancements, challenges remain, including the need for standardized procedures, harmonization of data, and the translation of theoretical models into clinical practice. Additionally, ensuring that AI-driven models are generalizable and applicable across diverse populations is crucial for their successful implementation in clinical settings [27].

6.3. Ethical and Social Considerations

The growing use of genetic data in AD prediction raises important ethical and social concerns, particularly related to privacy, data security, and the risk of genetic discrimination. As genetic testing becomes more widespread, safeguarding individuals' genetic information from misuse, especially in contexts like insurance and employment, is paramount. The possibility of data breaches adds to the concern, as sensitive information related to genetics, lifestyle, and environment could be exploited inappropriately, leading to unforeseen consequences.

Informed consent is another critical issue, especially for individuals who may develop cognitive impairments and lose the ability to make decisions over time. Ensuring that these individuals have adequately consented to genetic testing and data use poses ethical challenges, particularly as their condition progresses.

Public acceptance of genetic testing and predictive models is also not guaranteed. Concerns over the potential for false positives or over-reliance on genetic data may limit the adoption of these tools in clinical practice. Addressing these ethical issues while maintaining stringent data privacy standards will be key to ensuring the responsible use of predictive models in AD research and treatment.

7. Conclusion

Alzheimer's disease is a complex, multifactorial disorder with a substantial genetic component. Key genes, such as APOE, PSEN1, PSEN2, APP, CLU, PICALM, and CR1, are closely linked to AD risk, and understanding their roles has provided critical insights into disease progression. Databases like ADNI, AlzGene, and NACC offer valuable genetic and clinical data, which, when combined with neuroimaging technologies like structural MRI, functional MRI, and PET, help elucidate how genetic factors contribute to AD pathology.

Predictive tools, such as polygenic risk scores (PRS) and machine learning models—including support vector machines (SVM), random forests (RF), convolutional neural networks (CNN), autoencoders (AE), and deep learning—have shown potential in predicting the onset and progression of AD. However, significant challenges remain in integrating diverse data types, improving prediction accuracy across populations, and addressing the ethical concerns that arise from the use of genetic data.

Looking forward, the future of AD research lies in developing personalized therapies and predictive models that incorporate genetic, environmental, and lifestyle factors. As data integration techniques and computational models advance, these tools will likely play a pivotal role in early detection and personalized treatment strategies for AD. By improving the accuracy of predictive models and addressing ethical considerations, we can move closer to mitigating the burden of Alzheimer's disease through more effective, individualized care.

References

[1] García-Navarro, E. B., Buzón-Pérez, A., & Cabillas-Romero, M. (2022). Effect of Music Therapy as a Non-Pharmacological Measure Applied to Alzheimer's Disease Patients: A Systematic Review. Nursing Reports, 12 (4), 775 – 790. https: //doi.org/10.3390/nursrep12040076.

[2] Prince, M., Wimo, A., Guerchet, M., Ali, G. C., Wu, Y. T., & Prina, M. (2015). World Alzheimer Report 2015. The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends (Doctoral dissertation, Alzheimer's Disease International).

[3] Bellenguez, C., Kucukali, F., Jansen, I. E., Kleineidam, L., Moreno-Grau, S., Amin, N., Naj, A. C., Campos-Martin, R., Grenier-Boley, B., Andrade, V., Holmans, P. A., Boland, A., Damotte, V., Van Der Lee, S. J., Costa, M. R., Kuulasmaa, T., Yang, Q., De Rojas, I., Bis, J. C., . . . Lambert, J. (2022). New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 54 (4), 412 – 436. https: //doi.org/10.1038/s41588 - 022 - 01024 - z.

[4] Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M., Diaz-Cintra, S., Pacheco-Herrero, M., Luna-Muñoz, J., & Soto-Rojas, L. O. (2023).

[5] Raulin, A., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C. (2022). ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. Molecular Neurodegeneration, 17 (1). https: //doi.org/10.1186/s13024 - 022 - 00574 - 4.

[6] Liu, E., Zhang, Y., & Wang, J. (2024). Updates in Alzheimer's disease: from basic research to diagnosis and therapies. Translational Neurodegeneration, 13 (1). https: //doi.org/10.1186/s40035 - 024 – 00432 - x.

[7] Angelopoulou, E., Paudel, Y. N., Papageorgiou, S. G., & Piperi, C. (2021). APOE genotype and Alzheimer's Disease: the influence of lifestyle and environmental factors. ACS Chemical Neuroscience, 12 (15), 2749 – 2764. https://doi.org/10.1021/acschemneuro.1c00295.

[8] Van Giau, V., Bagyinszky, E., Yang, Y. S., Youn, Y. C., An, S. S. A., & Kim, S. Y. (2019). Genetic analyses of early-onset Alzheimer's disease using next generation sequencing. Scientific Reports, 9 (1). https: //doi.org/10.1038/s41598 - 019 - 44848 - 2.

[9] Jun, G., Naj, A. C., Beecham, G. W., Wang, L., Buros, J., Gallins, P. J., Buxbaum, J. D., Ertekin-Taner, N., Fallin, M. D., Friedland, R., Inzelberg, R., Kramer, P., Rogaeva, E., St George-Hyslop, P., Cantwell, L. B., Dombroski, B. A., Saykin, A. J., Reiman, E. M., Bennett, D. A., . . . Schellenberg, G. D. (2010). Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk LOCI and reveals interactions with APOE genotypes. Archives of Neurology, 67 (12), 1473. https: //doi.org/10.1001/archneurol.2010.201.

[10] Weber, C. J., Carrillo, M. C., Jagust, W., Jack, C. R., Shaw, L. M., Trojanowski, J. Q., Saykin, A. J., Beckett, L. A., Sur, C., Rao, N. P., Mendez, P. C., Black, S. E., Li, K., Iwatsubo, T., Chang, C., Sosa, A. L., Rowe, C. C., Perrin, R. J., Morris, J. C., . . . Weiner, M. W. (2021). The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI-3 updates and global perspectives. Alzheimer S & Dementia Translational Research & Clinical Interventions, 7 (1). https: //doi.org/10.1002/trc2.12226.

[11] ALZFORUM | NETWORKING FOR a CURE. (2024, September 6). https://www.alzforum.org/ Alzheimer's Disease: An updated overview of its genetics. International Journal of Molecular Sciences, 24 (4), 3754. https://doi.org/10.3390/ijms24043754.

[12] Beekly, D. L., Ramos, E. M., Van Belle, G., Deitrich, W., Clark, A. D., Jacka, M. E., Kukull, W. A., & Centers, N. D. (2004). The National Alzheimer's Coordinating Center (NACC) Database: an Alzheimer disease database. PubMed, 18 (4), 270 – 277. https: //pubmed.ncbi.nlm.nih.gov/15592144.

[13] Karlsson, I. K., Escott-Price, V., Gatz, M., Hardy, J., Pedersen, N. L., Shoai, M., & Reynolds, C. A. (2022). Measuring heritable contributions to Alzheimer's disease: polygenic risk score analysis with twins. Brain Communications, 4 (1). https://doi.org/10.1093/braincomms/fcab308

[14] Mosconi, L. (2013). Glucose metabolism in normal aging and Alzheimer's disease: methodological and physiological considerations for PET studies. Clinical and Translational Imaging, 1 (4), 217 – 233. https: //doi.org/10.1007/s40336 - 013 - 0026 - y.

[15] Van Oostveen, W. M., & De Lange, E. C. M. (2021). Imaging Techniques in Alzheimer's Disease: A review of applications in early diagnosis and longitudinal monitoring. International Journal of Molecular Sciences, 22 (4), 2110. https: //doi.org/10.3390/ijms22042110.

[16] Li, L., Yu, X., Sheng, C., Jiang, X., Zhang, Q., Han, Y., & Jiang, J. (2022). A review of brain imaging biomarker genomics in Alzheimer's disease: implementation and perspectives. Translational Neurodegeneration, 11 (1). https: //doi.org/10.1186/s40035 - 022 - 00315 - z.

[17] Mohan, A., Roberto, A. J., Mohan, A., Lorenzo, A., Jones, K., Carney, M. J., Liogier-Weyback, L., Hwang, S., & Lapidus, K. A. (2016). The Significance of the Default Mode Network (DMN) in Neurological and Neuropsychiatric Disorders: A Review. The Yale journal of biology and medicine, 89 (1), 49 – 57.

[18] Jeong, J. (2004). EEG dynamics in patients with Alzheimer's disease. Clinical Neurophysiology, 115 (7), 1490 – 1505. https://doi.org/10.1016/j.clinph.2004.01.001.

[19] Leonenko, G., Baker, E., Stevenson-Hoare, J., Sierksma, A., Fiers, M., Williams, J., De Strooper, B., & Escott-Price, V. (2021). Identifying individuals with high risk of Alzheimer's disease using polygenic risk scores. Nature Communications, 12 (1). https: //doi.org/10.1038/s41467 - 021 – 24082 - z.

[20] Baker, E., & Escott-Price, V. (2020). Polygenic risk scores in Alzheimer's Disease: current applications and future directions. Frontiers in Digital Health, 2. https: //doi.org/10.3389/fdgth.2020.00014.

[21] Zhao, Z., Chuah, J. H., Lai, K. W., Chow, C., Gochoo, M., Dhanalakshmi, S., Wang, N., Bao, W., & Wu, X. (2023). Conventional machine learning and deep learning in Alzheimer's disease diagnosis using neuroimaging: A review. Frontiers in Computational Neuroscience, 17. https: //doi.org/10.3389/fncom.2023.1038636.

[22] Khedher, L., Ramírez, J., Górriz, J., Brahim, A., & Segovia, F. (2015). Early diagnosis of Alzheimer's disease based on partial least squares, principal component analysis and support vector machine using segmented MRI images. Neurocomputing, 151, 139 – 150. https: //doi.org/10.1016/j.neucom.2014.09.072.

[23] Chen, H., Chen, J., Li, J., Huang, H., Chen, X., Zhang, H., & Chen, C. Y. (2019). Deep learning and random forest approach for finding the optimal traditional Chinese medicine formula for treatment of Alzheimer's disease. Journal of Chemical Information and Modeling, 59 (4), 1605 – 1623. https: //doi.org/10.1021/acs.jcim.9b00041.

[24] Castellano, G., Esposito, A., Lella, E., Montanaro, G., & Vessio, G. (2024). Automated detection of Alzheimer's disease: a multi-modal approach with 3D MRI and amyloid PET. Scientific Reports, 14(1). https: //doi.org/10.1038/s41598 - 024 - 56001 - 9.

[25] Venugopalan, J., Tong, L., Hassanzadeh, H. R., & Wang, M. D. (2021). Multimodal deep learning models for early detection of Alzheimer's disease stage. Scientific Reports, 11 (1). https: //doi.org/10.1038/s41598 - 020 - 74399 - w.

[26] Kodam, P., Swaroop, R. S., Pradhan, S. S., Sivaramakrishnan, V., & Vadrevu, R. (2023). Integrated multi-omics analysis of Alzheimer's disease shows molecular signatures associated with disease progression and potential therapeutic targets. Scientific Reports, 13 (1). https: //doi.org/10.1038/s41598 - 023 - 30892 - 6 020315.

[27] Silva-Spínola, A., Baldeiras, I., Arrais, J. P., & Santana, I. (2022). The road to personalized medicine in Alzheimer's disease: the use of artificial intelligence. Biomedicines, 10 (2), 315. https: //doi.org/10.3390/biomedicines10.